摘要
目的:对两种不同给药方案治疗儿童支气管肺炎进行药物经济学评价。方法:将67例支气管肺炎患儿分为A、B两组。A组32例,采用头孢曲松-头孢克洛序贯治疗;B组35例,采用头孢曲松连续静脉滴注。并对两种给药方案采用药物经济学中最小成本分析法进行分析。结果:两组在临床疗效方面无显著差异(P>0.05);A组在人均抗生素费用、住院治疗费用及总医疗费用方面均明显低于B组(P<0.01)。结论:采用头孢曲松-头孢克洛序贯治疗儿童支气管肺炎,不但安全有效,而且更加经济合理。
Objective To pharmacoeconomically evaluate two medications on bronchopneumonia in children. Methods 67 cases with bronchopneumonia were divided into two groups A and B. Group A includes 32 cases was accepted sequential therapy of Cefriaxone & Cefaclor while group B includes 35 cases with successive intravenous Ceftriaxone. Using cost-minimization analysis two therapeutic schems were compared. Results The effectiveness had not significant difference in two groups P>0.05the reduced average cost of antibiotic cost for treatment during hospitalization and total cost for treatment were significant in group A than group B P<0.01. Conclusion The present study showed that sequential therapy with Ceftriaxone & Cefaclor is a safe effective and economic medication on bronchopneumonia in children.
出处
《天津医科大学学报》
2005年第2期224-225,231,共3页
Journal of Tianjin Medical University
关键词
序贯治疗
药物经济学
最小成本分析
Sequence treatment Pharmacoeconomics Cost-minimization analysis
